Understanding how SHP2 and PLCγ1 affect calcium signaling in pancreatic cancer
Investigating the role of SHP2-PLCG1 interaction in PDAC calcium signaling and metabolism
This study is looking at how two proteins, SHP2 and PLCγ1, work together and affect calcium signaling in pancreatic cancer, with the hope of finding new ways to treat this tough disease and help patients live better lives.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10912502 on NIH RePORTER |
What this research studies
This research investigates the interaction between SHP2 and PLCγ1 and its impact on calcium signaling in pancreatic ductal adenocarcinoma (PDAC). By exploring how these proteins influence tumor progression and metabolism, the study aims to uncover new therapeutic targets for this aggressive cancer. Patients may benefit from insights that could lead to innovative treatments that disrupt the cancer's growth mechanisms. The research employs advanced cellular and molecular techniques to analyze the effects of manipulating these interactions in PDAC cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
Not a fit: Patients with other types of cancer or those without pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with pancreatic cancer.
How similar studies have performed: While the specific interaction of SHP2 and PLCγ1 in PDAC is a novel approach, similar studies targeting upstream regulators of cancer signaling pathways have shown promise in other cancers.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Walsh, Richard Mckinnon — University of Kansas Medical Center
- Study coordinator: Walsh, Richard Mckinnon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.